Compare Regeneron Pharmaceuticals Inc (REGN) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Direxion Daily TSLA Bull 2X Shares trades at $10.06. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| REGN | TSLL | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $812.27 | $23.03 |
52-Week Low | $545.46 | $10.29 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
TSLL is trading at $10.72, down 5.84% over the past day, with a bearish technical signal from moving averages and neutral oscillators. Key support lies at $10 and resistance at $11. The company has announced a future dividend of $0.10 per share scheduled for June 30, 2026. Recent news highlights focus on Tesla's upcoming earnings and related ETF movements, which may influence TSLL's performance given its thematic exposure.
The outlook for TSLL is cautious due to bearish technical indicators and reliance on Tesla's earnings catalyst. Investment opportunities hinge on positive earnings surprises from Tesla boosting the ETF, while risks include continued technical weakness and broader market volatility affecting leveraged ETF performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
